Pharmaceutical compositions comprising anti miRNA antisense oligonucleotides

Disclosed is a single-stranded oligonucleotide 8 to 24 nucleotides in length capable of reducing an effective amount of a miRNA in vitro or in a non-human cell or non-human organism, wherein said single stranded oligonucleotide comprises: (i) a sequence that is complementary to a sequence of said mi...

Full description

Saved in:
Bibliographic Details
Main Authors KEARNEY, PHIL, KAUPPINEN, SAKARI, ELMEN, JOACIM
Format Patent
LanguageEnglish
Published 28.03.2013
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
DERIVATIVES THEREOF
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
SUGARS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Disclosed is a single-stranded oligonucleotide 8 to 24 nucleotides in length capable of reducing an effective amount of a miRNA in vitro or in a non-human cell or non-human organism, wherein said single stranded oligonucleotide comprises: (i) a sequence that is complementary to a sequence of said miRNA; (ii) a sequence comprising not more than 4 consecutive 2'-deoxyribose nucleoside (DNA) units; (iii) a sequence comprising more than 4 consecutive Locked Nucleic Acid (LNA) units; (iv) at least 30% of constituent nucleotides as LNA units; and (v) at least one internucleoside linkage group comprising a phosphorothioate, subject to the proviso that the single-stranded oligonucleotide does not comprise a core DNA sequence of 3'-ctcaca-5' from positions two to seven or from positions three to eight thereof counting from the 3' end of said oligonucleotide.
Bibliography:Application Number: NZ20070594605